Greater flexibility for people with systemic lupus erythematosus

Company expects two‑year dfs data by q1 2028

New authorisation offers additional option for patients with lvef ≥40%

Partnership to develop next‑generation T‑cell engagers for solid tumours

First patient dosed as DOMISOL study grows beyond Australia

Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED

Study expands development of the antibody into hepatocellular carcinoma

Updated dosing offers meaningful clinical benefit

Company says treatment shows strong efficacy and convenient dosing profile

Specialist group to review preclinical and clinical proposals ahead of funding decision